Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley Acquires 8,600 Shares

Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley purchased 8,600 shares of the stock in a transaction that occurred on Thursday, April 25th. The shares were acquired at an average cost of $3.24 per share, with a total value of $27,864.00. Following the completion of the transaction, the senior vice president now owns 188,718 shares in the company, valued at $611,446.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Abeona Therapeutics Stock Up 2.2 %

Shares of Abeona Therapeutics stock opened at $3.26 on Friday. Abeona Therapeutics Inc has a 52-week low of $2.83 and a 52-week high of $9.01. The company has a 50-day simple moving average of $7.31 and a two-hundred day simple moving average of $5.61.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.13). As a group, analysts anticipate that Abeona Therapeutics Inc will post -2.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Simplex Trading LLC raised its holdings in Abeona Therapeutics by 1,889.9% in the third quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 13,418 shares during the last quarter. Jump Financial LLC purchased a new position in shares of Abeona Therapeutics during the fourth quarter valued at approximately $199,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of Abeona Therapeutics during the third quarter valued at approximately $648,000. Worth Venture Partners LLC raised its holdings in shares of Abeona Therapeutics by 76.6% during the third quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 121,969 shares during the last quarter. Finally, Barclays PLC raised its holdings in shares of Abeona Therapeutics by 100.0% during the third quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after purchasing an additional 185,638 shares during the last quarter. 80.56% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $36.00 price target on shares of Abeona Therapeutics in a research report on Tuesday. StockNews.com cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.